EDWARDS LIFESCIENCES CORPORATION
Reconciliation of GAAP to Non-GAAP Financial Information

<table>
<thead>
<tr>
<th>(in millions, except per share data)</th>
<th>Three Months Ended March 31,</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>2008</td>
</tr>
<tr>
<td>GAAP net income</td>
<td>$18.2</td>
</tr>
</tbody>
</table>

Reconciling items:

**Special charges, net**

1) Loss on sale of product line | 8.1 | - |
2) Litigation settlement         | 2.1 | - |
3) Realignment expenses, net     | (0.1) | - |

Total special charges, net        | 10.1 | - |

**Provision for income taxes**

Tax effect on non-GAAP adjustments (A) | 4.9 | - |

Total provision for income taxes, net | 4.9 | - |

Non-GAAP net income                | $33.2 | $33.2 |

**Non-GAAP earnings per share:**

Basic non-GAAP earnings per share | $0.59 | $0.57 |
Diluted non-GAAP earnings per share (B) | $0.56 | $0.54 |

**Non-GAAP weighted average shares outstanding:**

Basic                           | 56.1 | 57.9 |
Diluted                          | 61.2 | 63.5 |

Notes 1 - 3: See description of Special Charges, net on the previous page.

(A) The tax effect on non-GAAP adjustments is calculated using the relevant tax jurisdictions' statutory tax rates.

(B) Diluted non-GAAP earnings per share is calculated by adding back to net income $1.0 million for the quarter in interest expense related to the convertible debt, then dividing by the weighted average diluted shares outstanding.

Note: Numbers may not calculate due to rounding.